NEW YORK, May 5, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. (NASDAQ: IKT) on behalf of the company's shareholders. The investigation seeks to determine whether Inhibikase Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Inhibikase Therapeutics, Inc. and are interested in obtaining additional information about your rights and options, please visit us at: https://p ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. "David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 26-3407249 (State or other jurisdiction of ...

Exhibit 99.1 Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity — New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — March 27, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the yea ...

Core Viewpoint - Inhibikase Therapeutics, Inc. is advancing its clinical development of IkT-001 for pulmonary arterial hypertension (PAH) and has reported a net loss for 2024 while enhancing its management team to support growth [2][4][7]. Financial Results - The net loss for the year ended December 31, 2024, was $27.5 million, or $1.16 per share, compared to a net loss of $19.1 million, or $3.16 per share in 2023 [4][15]. - Research and development expenses increased to $17.2 million in 2024 from $13.6 million in 2023 [4][14]. - Selling, general and administrative expenses rose to $11.4 million in 2024 from $6.7 million in 2023 [5][14]. - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $97.5 million [5]. Recent Developments - The company closed a private placement in October 2024, raising approximately $110 million to support the late-stage clinical trial of IkT-001, with potential total gross proceeds of up to $275 million if warrants are exercised [7]. - The company received a "Study May Proceed" letter for the Phase 2b trial of IkT-001 in September 2024, indicating progress in its clinical development [7]. - The management team was strengthened with the appointments of Chris Cabell and John Adams, who are expected to accelerate the development of IkT-001 [2][7].

A downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts ab ...

Core Insights - Inhibikase Therapeutics has appointed Chris Cabell, M.D. as President and Head of Research & Development, and John Adams, Ph.D. as Chief Scientific Officer, both with extensive experience in pulmonary arterial hypertension (PAH) [1][2] - The company aims to accelerate the development of IkT-001, an oral prodrug of imatinib mesylate, for the treatment of PAH, with plans to execute a Phase 2 clinical trial [2][6] - Vince Aurentz has joined the Board of Directors, bringing significant experience in corporate strategy and business development from his previous roles in the biopharmaceutical sector [2][5] Leadership Appointments - Chris Cabell, M.D. has a background as Chief Medical Officer at Arena Pharmaceuticals and Chief Executive Officer at CorHepta Pharmaceuticals, with a focus on cardiology and PAH [3] - John Adams, Ph.D. co-founded CorHepta and previously held senior positions at Iambic Therapeutics and Reneo Pharmaceuticals, specializing in research and translational science [4] - Vince Aurentz has held key leadership roles, including Executive Vice President at Arena Pharmaceuticals, contributing to corporate strategy and business development [5] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary diseases [6] - The company's lead product, IkT-001, targets PAH and is positioned as a potential innovative therapeutic option for patients suffering from this condition [6]

-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective February 14, 202 ...

Core Insights - Inhibikase Therapeutics has secured transformative financing of up to $275 million to advance its drug IkT-001Pro into late-stage clinical trials for Pulmonary Arterial Hypertension (PAH) [1][3] - The company aims to improve the safety and tolerability profile of imatinib, which has previously faced approval challenges for PAH treatment [2][3] - Upcoming milestones include the reporting of 201 Trial results in Q4 2024, which evaluates risvodetinib in untreated Parkinson's disease [1][3] Financing and Investment - The financing includes a private placement of approximately $110 million, with potential aggregate financing of up to $275 million upon full cash exercise of accompanying warrants [3] - The funds will support the execution of the Phase 2b '702' trial in PAH and general corporate purposes [3] - Notable additions to the Board of Directors include experienced leaders from biopharmaceutical development, enhancing the company's strategic capabilities [3] Clinical Development - IkT-001Pro has received a Study May Proceed letter from the FDA, allowing the company to advance its clinical development [3] - The active ingredient, imatinib, is believed to have disease-modifying potential for PAH, with IkT-001Pro expected to offer a better safety profile [3] - The company is enhancing its manufacturing processes to support late-stage clinical development, including new dosage forms and efficient production methods [3] Financial Performance - For Q3 2024, the company reported a net loss of $5.8 million, or $0.65 per share, compared to a net loss of $4.6 million, or $0.75 per share in Q3 2023 [4][10] - Research and development expenses increased to $4.2 million in Q3 2024 from $3.23 million in Q3 2023 [4][10] - Selling, general and administrative expenses remained relatively stable at $1.6 million compared to $1.62 million in the same quarter of the previous year [5][10] Cash Position - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $3.2 million, excluding the gross proceeds from the recent financing [5]

IkT-001Pro Development and Clinical Trials - The company completed a bioequivalence clinical trial for IkT-001Pro in 2023, establishing bioequivalence to 400 mg imatinib mesylate with a 600 mg dose of IkT-001Pro[78] - A dose between 800 mg and 900 mg of IkT-001Pro is preferred to deliver a dose equivalent to 600 mg imatinib mesylate[78] - The FDA acknowledged the 505(b)(2) pathway as appropriate for IkT-001Pro approval, pending formal review of clinical data[78] - IkT-001Pro and imatinib mesylate exhibit similar behavior toward gut transporters P-glycoprotein (PGP) and Breast Cancer Resistance Protein (BCRP)[79] - The company discussed alternate dosage forms for IkT-001Pro to prevent medication errors with imatinib mesylate[79] - The company met with the FDA Hematological Malignancy Review Team on January 19, 2024, to discuss IkT-001Pro's path to approval[78] - The company's multi-therapeutic pipeline includes IkT-001Pro for Pulmonary Arterial Hypertension (PAH)[77] - The company has patent protection in the United States until 2033 for IkT-001Pro[87] Risvodetinib Development and Clinical Trials - The company initiated Phase 2 201 trial for risvodetinib (IkT-148009) as a treatment for Parkinson's disease, with results expected in Q4 2024[77] - The company completed the Phase 2 201 trial for risvodetinib on October 6, 2024[77] - The Phase 2 '201 Trial' for risvodetinib in untreated Parkinson's disease was completed on October 6, 2024, with outcomes expected in Q4 2024[81] - The Company received a $0.39 million grant from the National Institute of Neurological Diseases and Stroke for risvodetinib studies in MSA[82] - The tablet formulation of risvodetinib nearly doubles the concentration delivered, potentially improving safety and tolerability[84] - The company's multi-therapeutic pipeline includes risvodetinib for Parkinson's disease[77] - The Company plans to submit regulatory documents for risvodetinib to European Union authorities in 2024 or 2025[82] - The company has patent protection in the United States until 2036 for risvodetinib[87] Financial Performance and Expenses - The Company closed a private placement with an initial investment of approximately $110 million, potentially reaching up to $275 million if warrants are exercised[80] - Research and development expenses for PAH increased by $814,424 in 2024 compared to 2023[95] - Total research and development expenses for the three months ended September 30, 2024, were $4,189,873, a 29.9% increase from 2023[100] - The Company's net loss for the three months ended September 30, 2024, was $5,778,066, a 25.7% increase from 2023[100] - Grant revenue for the three months ended September 30, 2024, decreased by $79,569 or 100.0% to $0 from $79,569 in the prior comparable period[101] - Research and development expenses increased by $964,322 or 29.9% to $4,189,873 from $3,225,551 in the prior comparable period[102] - Selling, general and administrative expenses increased by $14,709 or 0.9% to $1,637,603 from $1,622,894 in the prior comparable period[103] - Interest income decreased by $124,267 or 71.6% to $49,410 from $173,677 in the prior comparable period[104] - Grant revenue for the nine months ended September 30, 2024, decreased by $260,500 or 100% to $0 from $260,500 in the prior comparable period[106] - Research and development expenses decreased by $598,386 or 5.6% to $10,016,982 from $10,615,368 in the prior comparable period[107] - Selling, general and administrative expenses increased by $312,028 or 5.9% to $5,643,386 from $5,331,358 in the prior comparable period[108] - Interest income decreased by $562,224 or 67.3% to $273,059 from $835,283 in the prior comparable period[109] - The Company raised approximately $110 million in gross proceeds from its October 2024 Offering[110] - Net cash flows used in operating activities for the nine months ended September 30, 2024, totaled $13,802,492[117] - Net cash flows provided by financing activities for the nine months ended September 30, 2024, totaled $3.793 billion, consisting of $3.8 million from the issuance of common stock and pre-funded warrants[121] - Net cash flows provided by financing activities for the nine months ended September 30, 2023, totaled $8.543 billion, primarily from the issuance of common stock and pre-funded warrants[122] Market and Industry Insights - The global PAH market size was valued at $7.66 billion in 2023 and is estimated to grow at a CAGR of 5.4% between 2024 to 2030[80] - The company's clinical trials and product development are focused on neurodegenerative and cardiopulmonary diseases[77] Operational and Financial Details - The company's total lease obligation for its Lexington office space is $153,288, with minimum annual rental obligations of $38,322 for fiscal year 2024 and $114,966 for fiscal year 2025[123] - Research and development expenses include costs for employee-related expenses, external R&D arrangements, technology acquisition, and other direct and allocated expenses[125] - A significant portion of R&D expenses is attributed to external costs, including clinical studies, preclinical studies, and consulting services[126] - The company accrues and estimates R&D expenses based on costs incurred, with adjustments made as actual costs become known[127] - The company does not have any off-balance sheet arrangements[123] - Financial statements are prepared in accordance with US GAAP, requiring significant estimates and judgments that may impact reported amounts[124] - The company is not required to provide quantitative and qualitative market risk disclosures as a smaller reporting company[129]